Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline

Stock Track

06/24

MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.

The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.

Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1111227454"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111227454\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111227454?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111227454","market":"hk","top_or_hot":-1,"title":"Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline","media":"Stock Track","content":"<p>MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.</p><p>The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.</p><p>Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MICOT PHARMA-B Soars 89.56% in Early Trading on IPO Debut Amid Heavy Oversubscription and Promising Pipeline\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-06-24 09:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.</p><p>The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.</p><p>Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02335","symbol_name":"麥科醫藥-B","start_time":0,"source_url":"","article_id":"1111227454","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111227454","pubTimestamp":1782264920,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02335":"麦科医药-B"},"translate_title":"股票追踪|Micot Pharma-B IPO首秀早盘飙升89.56%，超额认购严重，管线前景看好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02335":1},"content_text":"MICOT PHARMA-B (02335) surged 89.56% in early trading as it made its debut on the Hong Kong Stock Exchange.The dramatic rise was fueled by extraordinary investor demand, with the Hong Kong public offering oversubscribed 1,181.46 times. The company raised net proceeds of approximately HK$989 million to HK$1.067 billion from the issuance of 58.05 million shares at an offer price of HK$18.20 per share.Investor enthusiasm is also driven by the company's clinical-stage pipeline. Its lead product, MT1013, is a dual-target receptor agonist peptide currently in Phase III trials for the treatment of secondary hyperparathyroidism in chronic kidney disease patients, with commercialization targeted for early 2028.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}